uniQure Announces Company Presentations at Upcoming October Conferences
October 02 2017 - 7:00AM
uniQure N.V. (NASDAQ:QURE) a leading gene therapy company advancing
transformative therapies for patients with severe medical needs,
today announced company presentations at the following conferences
taking place in October:
Alliance for Regenerative Medicine (ARM)
2017 Cell & Gene Meeting on the Mesa, October 4 – 6 2017, at
the Estancia La Jolla Hotel & Spa in La Jolla,
California.
• Jonathan Garen, chief business
officer, will present a corporate overview on Wednesday, October
4th, 2017 at 3:30 p.m. PDT. The live webcast can be accessed
through the link displayed in the Investor section of the uniQure
website. The webcast replay will be available for at least two
weeks following the live event.
European Society of Gene & Cell
Therapy (EGSCT) 25th Anniversary Congress, October 17 – 20, 2017,
at the BCC Berlin in Berlin, Germany.
• Members of the uniQure research &
development team will be presenting new data focused on the
progress and optimization of uniQure’s lead programs in gene
therapy:
- Title: AAV5-miHTT gene therapy demonstrates
sustained huntingtin lowering and functional improvement in
Huntington disease mouse models Session
Title: 1b - Ocular and Central Nervous System Gene and
Cell Therapy IDate and Time: Wednesday, October
18th, 2017, from 8:30 – 10:40 am CET
- Title: Engineered AAV capsids are successfully
produced through the innovative approach of combining directed
evolution and the BEVS expression system. Poster and
Date: P347 – Wednesday, October 18th, 2017.
- Title: Development and characterization of
MFP-inducible GeneSwitch system for AAV5 gene therapy of chronic
diseases in the liverPoster and Date: P160 –
Thursday, October 19th, 2017
4th Animal Models
of Neurodegenerative Disease Conference, October 22 – 24,
2017, at Chateau Liblice, Czech Republic.
• Members of the uniQure research
& development team will be presenting new data focused on
progress in technologies and development of animal models in gene
therapy for Huntington’s disease:
- Title: Establishing proof-of-concept of gene
therapy for Huntington’s disease.Date: Tuesday,
October 24th, 2017, morning session.
- Title: AAV-mediated delivery in large
animals.Date: Monday, October 23rd, 2017,
afternoon session.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary and partnered gene therapies to treat patients with
hemophilia, Huntington’s disease and cardiovascular diseases.
www.uniQure.com
uniQure Contacts:
Maria E.
Cantor |
Eva M.
Mulder |
Tom
Malone |
Direct:
339-970-7536 |
Direct: +31 20 240
6103 |
Direct: 339-970-7558 |
Mobile:
617-680-9452 |
Mobile: +31 6 52 33 15
79 |
Mobile: 339-223-8541 |
m.cantor@uniQure.com |
e.mulder@uniQure.com |
t.malone@uniQure.com |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024